Oral TPI 287: Phase Ib/II start

This summer, TPPH will begin a Phase Ib/II trial in refractory cancer patients. The trial will evaluate an initial oral dose of TPI 287 followed 1 week later by an intravenous dose of TPI 287 or vice ...